Brief: J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro

Johnson & Johnson

23/09/2026 15:34

Sept 23 (Reuters) - Johnson & Johnson JNJ.N:
NEW MODEL-BASED ANALYSIS FURTHER SUPPORTS THE POTENTIAL OF TECVAYLI® (TECLISTAMAB-CQYV) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) TO REDEFINE LONG-TERM SURVIVAL EXPECTATIONS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA
J&J - ANALYSIS ESTIMATES 87% OF TECVAYLI PLUS DARZALEX FASPRO PATIENTS HAVE COMPARABLE MORTALITY RISK TO GENERAL POPULATION
J&J - TECVAYLI PLUS DARZALEX FASPRO REDUCES MULTIPLE MYELOMA PROGRESSION RISK BY 90% VERSUS STANDARD OF CARE
Source text: ID:nPnbHbsDHa
Further company coverage: JNJ.N

 ((Reuters.Briefs@thomsonreuters.com;))